Recent trends of NFκB decoy oligodeoxynucleotide-based nanotherapeutics in lung diseases

Recent trends of NFκB decoy oligodeoxynucleotide-based nanotherapeutics in lung diseases.

Full text not available from this repository.
Item Type: Review
Status: Published
Official URL: https://doi.org/10.1016/j.jconrel.2021.08.010
Journal or Publication Title: Journal of Controlled Release
Volume: 337
Page Range: pp. 629-644
Date: 10 September 2021
Divisions: UTS Centre for Inflammation
Depositing User: General Admin
Identification Number: 10.1016/j.jconrel.2021.08.010
ISSN: 01683659
Date Deposited: 07 Dec 2021 08:13
Abstract:

Nuclear factor κB (NFκB) is a unique protein complex that plays a major role in lung inflammation and respiratory dysfunction. The NFκB signaling pathway, therefore becomes an avenue for the development of potential pharmacological interventions, especially in situations where chronic inflammation is often constitutively active and plays a key role in the pathogenesis and progression of the disease. NFκB decoy oligodeoxynucleotides (ODNs) are double-stranded and carry NFκB binding sequences. They prevent the formation of NFκB-mediated inflammatory cytokines and thus have been employed in the treatment of a variety of chronic inflammatory diseases. However, the systemic administration of naked decoy ODNs restricts their therapeutic effectiveness because of their poor pharmacokinetic profile, instability, degradation by cellular enzymes and their low cellular uptake. Both structural modification and nanotechnology have shown promising results in enhancing the pharmacokinetic profiles of potent therapeutic substances and have also shown great potential in the treatment of respiratory diseases such as asthma, chronic obstructive pulmonary disease and cystic fibrosis. In this review, we examine the contribution of NFκB activation in respiratory diseases and recent advancements in the therapeutic use of decoy ODNs. In addition, we also highlight the limitations and challenges in use of decoy ODNs as therapeutic molecules, cellular uptake of decoy ODNs, and the current need for novel delivery systems to provide efficient delivery of decoy ODNs. Furthermore, this review provides a common platform for discussion on the existence of decoy ODNs, as well as outlining perspectives on the latest generation of delivery systems that encapsulate decoy ODNs and target NFκB in respiratory diseases.

Keywords: Decoy oligodeoxynucleotide; Novel delivery systems; Nuclear factor kappa B; Respiratory disorder.

Copyright © 2021 Elsevier B.V. All rights reserved.

Creators:
Creators
Email
Mehta, Meenu
UNSPECIFIED
Paudel, Keshav Raj
UNSPECIFIED
Shukla, Shakti Dhar
UNSPECIFIED
Allam, Venkata Sita Rama Raju
UNSPECIFIED
Kannaujiya, Vinod Kumar
UNSPECIFIED
Panth, Nisha
UNSPECIFIED
Das, Amlan
UNSPECIFIED
Parihar, Vipan Kumar
UNSPECIFIED
Chakraborty, Amlan
UNSPECIFIED
Ali, Md Khadem
UNSPECIFIED
Jha, Niraj Kumar
UNSPECIFIED
Xenaki, Dikaia
UNSPECIFIED
Su, Qian Peter
UNSPECIFIED
Wich, Peter Richard
UNSPECIFIED
Adams, Jon
UNSPECIFIED
Hansbro, Philip Michael
UNSPECIFIED
Chellappan, Dinesh Kumar
UNSPECIFIED
Oliver, Brian Gregory George
UNSPECIFIED
Dua, Kamal
UNSPECIFIED
Last Modified: 07 Dec 2021 08:13
URI: https://eprints.centenary.org.au/id/eprint/1181

Actions (login required)

View Item View Item